Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Zheng, Xiufen ^b   Popov, Igor ^b   Zhang, Xusheng ^b   Wang, Hongmei ^a   Suzuki, Motohiko ^b   De Necochea Campion, Rosalia ^c   French, Peter W ^d   Chen, Di ^b   Siu, Leo ^b   Koos, David ^e   Inman, Robert D ^f   Min, Wei Ping ^a,b,g  

^a NANCHANG UNIVERSITY   (China)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c Medistem Inc   (United States)

^d Benitec Biopharma Limited   (Australia)

^e Entest BioMedical   (United States)

^f TORONTO WESTERN HOSPITAL   (Canada)

^g LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Autoimmunity; Collagen induced arthritis; Dendritic cells; IL 12; ShRNA

Indexed keywords

COLLAGEN TYPE 2; INTERLEUKIN 12; PROTEIN P53; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL INFILTRATION; CELL THERAPY; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; EXPRESSION VECTOR; GENE SILENCING; GENETIC TRANSFECTION; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATORY CELL; LYMPHOCYTE PROLIFERATION; MALE; MIXED LYMPHOCYTE REACTION; MOLECULAR CLONING; MOUSE; NONHUMAN; PLASMID; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; DBA MOUSE; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANIMALS; ANTIBODY FORMATION; ARTHRITIS, EXPERIMENTAL; COLLAGEN TYPE II; DENDRITIC CELLS; GENE SILENCING; IMMUNOLOGIC MEMORY; IMMUNOMODULATION; INTERLEUKIN-12; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; RNA, SMALL INTERFERING; T-LYMPHOCYTES; TRANSFECTION;

EID: 84856317306     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-19     Document Type: Article

References (60)

1. Abeles AM, Pillinger MH. The role of the synovial fibroblast in rheumatoid arthritis: cartilage destruction and the regulation of matrix metalloproteinases. Bull NYU Hospital Joint Diseases 2006, 64:20-24.
2. Smeets TJ, Barg EC, Kraan MC, Smith MD, Breedveld FC, Tak PP. Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann Rheum Dis 2003, 62:635-638. 10.1136/ard.62.7.635, 1754593, 12810425.
3. Smeets TJ, Kraan MC, Galjaard S, Youssef PP, Smith MD, Tak PP. Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA. Ann Rheum Dis 2001, 60:561-565. 10.1136/ard.60.6.561, 1753677, 11350843.
4. Cope AP, Schulze-Koops H, Aringer M. The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol 2007, 25:S4-S11.
5. Yamada H, Nakashima Y, Okazaki K, Mawatari T, Fukushi JI, Kaibara N, Hori A, Iwamoto Y, Yoshikai Y. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67:1299-1304.
6. Yamada H, Nakashima Y, Okazaki K, Mawatari T, Fukushi J, Oyamada A, Fujimura K, Iwamoto Y, Yoshikai Y. Preferential accumulation of activated Th1 cells not only in rheumatoid arthritis but also in osteoarthritis joints. J Rheumatol 2011, 38:1569-1575. 10.3899/jrheum.101355, 21532055.
7. Choosing Medications for Rheumatoid Arthritis Clinician's Guide. Comparative Effectiveness Review Summary Guides for Clinicians. Rockville (MD) 2007, Ahrq], Choosing Medications for Rheumatoid Arthritis.
8. Ichim TE, Harman RJ, Min WP, Minev B, Solano F, Rodriguez JP, Alexandrescu DT, De Necochea-Campion R, Hu X, Marleau AM, Riordan NH. Autologous stromal vascular fraction cells: a tool for facilitating tolerance in rheumatic disease. Cell Immunol 2010, 264:7-17. 10.1016/j.cellimm.2010.04.002, 20537320.
9. Ichim TE, Zheng X, Suzuki M, Kubo N, Zhang X, Min LR, Beduhn ME, Riordan NH, Inman RD, Min WP. Antigen-specific therapy of rheumatoid arthritis. Expert Opin Biol Ther 2008, 8:191-199. 10.1517/14712598.8.2.191, 18194075.
10. Sany J. Intravenous immunoglobulin therapy for rheumatic diseases. Curr Opin Rheumatol 1994, 6:305-310. 10.1097/00002281-199405000-00011, 8060767.
11. Bagchi D, Misner B, Bagchi M, Kothari SC, Downs BW, Fafard RD, Preuss HG. Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int J Clin Pharmacol Res 2002, 22:101-110.
12. Hauselmann HJ, Caravatti M, Seifert B, Wang K, Bruckner P, Stucki G, Michel BA. Can collagen type II sustain a methotrexate-induced therapeutic effect in patients with long-standing rheumatoid arthritis? A double-blind, randomized trial. Br J Rheumatol 1998, 37:1110-1117. 10.1093/rheumatology/37.10.1110, 9825751.
13. Kavanaugh A, Genovese M, Baughman J, Kivitz A, Bulpitt K, Olsen N, Weisman M, Matteson E, Furst D, van Vollenhoven R, et al. Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial. J Rheumatol 2003, 30:449-454.
14. Babatz J, Rollig C, Lobel B, Folprecht G, Haack M, Gunther H, Kohne CH, Ehninger G, Schmitz M, Bornhauser M. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother 2006, 55:268-276. 10.1007/s00262-005-0021-x, 16034561.
15. Holtl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C, Nussbaumer W, Falkensammer C, Bartsch G, Thurnher M. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 2005, 54:663-670. 10.1007/s00262-004-0629-2, 15918076.
16. Chen M, Li YG, Zhang DZ, Wang ZY, Zeng WQ, Shi XF, Guo Y, Guo SH, Ren H. Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study. World J Gastroenterol 2005, 11:1806-1808.
17. Prasad SJ, Farrand KJ, Matthews SA, Chang JH, McHugh RS, Ronchese F. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J Immunol 2005, 174:90-98.
18. Bulloch MN, Elayan MM, Renfroe HR. Sipuleucel-T: a therapeutic cancer vaccine for the treatment of castration- or hormone-refractory prostate cancer. Expert Rev Clin Pharmacol 2011, 4:685-692. 10.1586/ecp.11.60, 22111853.
19. Heng Y, Ma Y, Yin H, Duan L, Xiong P, Xu Y, Feng W, Fang M, Tan Z, Chen Y, et al. Adoptive transfer of FTY720-treated immature BMDCs significantly prolonged cardiac allograft survival. Transplant Int: Official J Eur Soc Organ Transplantation 2010, 23:1259-1270.
20. Mahnke K, Johnson TS, Ring S, Enk AH. Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J Dermatol Sci 2007, 46:159-167. 10.1016/j.jdermsci.2007.03.002, 17428639.
21. Popov I, Li M, Zheng X, San H, Zhang X, Ichim TE, Suzuki M, Feng B, Vladau C, Zhong R, et al. Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Therapy 2006, 8:R141.
22. Zheng X, Suzuki M, Ichim TE, Zhang X, Sun H, Zhu F, Shunnar A, Garcia B, Inman RD, Min W. Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J Immunol 2010, 184:6457-6464. 10.4049/jimmunol.0901717, 20435931.
23. Zheng X, Suzuki M, Zhang X, Ichim TE, Zhu F, Ling H, Shunnar A, Wang MH, Garcia B, Inman RD, Min WP. RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res Therapy 2010, 12:R13.
24. Rosengren AT, Nyman TA, Lahesmaa R. Proteome profiling of interleukin-12 treated human T helper cells. Proteomics 2005, 5:3137-3141. 10.1002/pmic.200401151, 16038020.
25. O'Garra A, Hosken N, Macatonia S, Wenner CA, Murphy K. The role of macrophage- and dendritic cell-derived IL12 in Th1 phenotype development. Res Immunol 1995, 146:466-472. 10.1016/0923-2494(96)83017-3, 8839147.
26. Trinchieri G. Immunobiology of interleukin-12. Immunol Res 1998, 17:269-278. 10.1007/BF02786451, 9479588.
27. Mauri C, Feldmann M, Williams RO. Down-regulation of Th1-mediated pathology in experimental arthritis by stimulation of the Th2 arm of the immune response. Arthritis Rheum 2003, 48:839-845. 10.1002/art.10832, 12632440.
28. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951-1957. 10.1084/jem.20030896, 2194162, 14662908.
29. Simpson PB, Mistry MS, Maki RA, Yang W, Schwarz DA, Johnson EB, Lio FM, Alleva DG. Cuttine edge: diabetes-associated quantitative trait locus, Idd4, is responsible for the IL-12p40 overexpression defect in nonobese diabetic (NOD) mice. J Immunol 2003, 171:3333-3337.
30. Trembleau S, Penna G, Gregori S, Giarratana N, Adorini L. IL-12 administration accelerates autoimmune diabetes in both wild-type and IFN-gamma-deficient nonobese diabetic mice, revealing pathogenic and protective effects of IL-12-induced IFN-gamma. J Immunol 2003, 170:5491-5501.
31. Gran B, Zhang GX, Rostami A. Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. Crit Rev Immunol 2004, 24:111-128. 10.1615/CritRevImmunol.v24.i2.20, 15581393.
32. Brok HP, van Meurs M, Blezer E, Schantz A, Peritt D, Treacy G, Laman JD, Bauer J. t Hart BA: Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol 2002, 169:6554-6563.
33. Kimura H, Tzou SC, Rocchi R, Kimura M, Suzuki K, Parlow AF, Rose NR, Caturegli P. Interleukin (IL)-12-driven primary hypothyroidism: the contrasting roles of two Th1 cytokines (IL-12 and interferon-gamma). Endocrinol 2005, 146:3642-3651.
34. Chen K, Wei Y, Sharp GC, Braley-Mullen H. Induction of experimental autoimmune thyroiditis in IL-12-/- mice. J Immunol 2001, 167:1720-1727.
35. Hill JA, Ichim TE, Kusznieruk KP, Li M, Huang X, Yan X, Zhong R, Cairns E, Bell DA, Min WP. Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol 2003, 171:691-696.
36. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002, 26:199-213. 10.1016/S1046-2023(02)00023-3, 12054897.
37. Zhu X, Imamura M, Tanaka J, Han CW, Hashino S, Imai K, Asano M, Nakane A, Minagawa T, Kobayashi M, et al. Effects of 15-deoxyspergualin in vitro and in vivo on cytokine gene expression. Transplantation 1994, 58:1104-1109.
38. Schurgers E, Billiau A, Matthys P. Collagen-Induced Arthritis as an Animal Model for Rheumatoid Arthritis: Focus on Interferon-gamma. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research 2011, 31:917-926.
39. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997, 159:4772-4780.
40. Butler DM, Malfait AM, Maini RN, Brennan FM, Feldmann M. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur J Immunol 1999, 29:2205-2212. 10.1002/(SICI)1521-4141(199907)29:07<2205::AID-IMMU2205>3.0.CO;2-Z, 10427983.
41. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, Cerutti A. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002, 3:822-829.
42. Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001, 166:3499-3505.
43. van den Berg WB. Animal models of arthritis. What have we learned?. J Rheumatol Suppl 2005, 72:7-9.
44. Pearson TC, Trambley J, Odom K, Anderson DC, Cowan S, Bray R, Lin A, Hollenbaugh D, Aruffo A, Siadak AW, et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002, 74:933-940. 10.1097/00007890-200210150-00006, 12394833.
45. Bonham CA, Peng L, Liang X, Chen Z, Wang L, Ma L, Hackstein H, Robbins PD, Thomson AW, Fung JJ, et al. Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol 2002, 169:3382-3391.
46. Li S, Thanikachalam M, Pang M, Kawaharada N, Aitouche A, Pham SM. A clinically relevant CTLA4-Ig-based regimen induces chimerism and tolerance to heart grafts. Ann Thorac Surg 2001, 72:1306-1310. 10.1016/S0003-4975(01)03066-1, 11603451.
47. Giannoukakis N, Bonham CA, Qian S, Chen Z, Peng L, Harnaha J, Li W, Thomson AW, Fung JJ, Robbins PD, Lu L. Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol Ther 2000, 1:430-437. 10.1006/mthe.2000.0060, 10933964.
48. Bertrand J, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 2002, 296:1000. 10.1016/S0006-291X(02)02013-2, 12200148.
49. Celotto AM, Graveley BR. Exon-specific RNAi: a tool for dissecting the functional relevance of alternative splicing. RNA 2002, 8:718-724. 10.1017/S1355838202021064, 1370291, 12088145.
50. Grishok A, Tabara H, Mello CC. Genetic requirements for inheritance of RNAi in C. elegans. Science 2000, 287:2494-2497. 10.1126/science.287.5462.2494, 10741970.
51. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553. 10.1126/science.1068999, 11910072.
52. Paul CP, Good PD, Winer I, Engelke DR. Effective expression of small interfering RNA in human cells. Nat Biotechnol 2002, 20:505-508. 10.1038/nbt0502-505, 11981566.
53. Devroe E, Silver PA. Retrovirus-delivered siRNA. BMC Biotechnol 2002, 2:15. 10.1186/1472-6750-2-15, 126223, 12199908.
54. Pardridge WM. Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin Biol Ther 2004, 4:1103-1113. 10.1517/14712598.4.7.1103, 15268677.
55. Yang D, Buchholz F, Huang Z, Goga A, Chen CY, Brodsky FM, Bishop JM. Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells. Proc Natl Acad Sci USA 2002, 99:9942-9947. 10.1073/pnas.152327299, 126604, 12096193.
56. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A, Mi S, Yam P, Stinson S, Kalos M, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Translational Med 2010, 2:36ra43.
57. Laderach D, Compagno D, Danos O, Vainchenker W, Galy A. RNA interference shows critical requirement for NF-kappa B p50 in the production of IL-12 by human dendritic cells. J Immunol 2003, 171:1750-1757.
58. Wong AW, Brickey WJ, Taxman DJ, van Deventer HW, Reed W, Gao JX, Zheng P, Liu Y, Li P, Blum JS, et al. CIITA-regulated plexin-A1 affects T-cell-dendritic cell interactions. Nat Immunol 2003, 4:891-898.
59. Li M, Zhang X, Zheng X, Lian D, Zhang ZX, Ge W, Yang J, Vladau C, Suzuki M, Chen D, et al. Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J Immunol 2007, 178:5480-5487.
60. Li M, Qian H, Ichim TE, Ge WW, Popov IA, Rycerz K, Neu J, White D, Zhong R, Min WP. Induction of RNA interference in dendritic cells. Immunol Res 2004, 30:215-230. 10.1385/IR:30:2:215, 15477662.